TY - JOUR
T1 - Canada's Assisted Human Reproduction Act
T2 - Pragmatic Reforms in Support of Research
AU - Bubela, Tania
AU - Kleiderman, Erika
AU - Master, Zubin
AU - Ogbogu, Ubaka
AU - Ravitsky, Vardit
AU - Zarzeczny, Amy
AU - Knoppers, Bartha Maria
N1 - Publisher Copyright:
© Copyright © 2019 Bubela, Kleiderman, Master, Ogbogu, Ravitsky, Zarzeczny and Knoppers.
PY - 2019/7/10
Y1 - 2019/7/10
N2 - Canada's Assisted Human Reproduction Act is long overdue for Parliamentary review. We argue that the current regulation of research using human reproductive materials is not proportionate, not responsive to the uncertain threats posed to human and environmental health and safety, and is not considerate of diverse values in a democratic society. We propose tailored regulatory carve-outs for in vitro research for currently prohibited activities, such as gene editing, and for the exercise of Ministerial Discretion for access by Canadians to experimental in vivo interventions that are currently prohibited, such as mitochondrial replacement therapy. Our recommendations are bounded by constitutional constraints that recognize political and practical challenges in keeping oversight of this research under Federal jurisdiction, whether conducted in academic or private sectors. The proposed nuanced regulatory scheme should be overseen by a new national Agency, modeled on a blend of the Canadian Stem Cell Oversight Committee and Assisted Human Reproduction Canada.
AB - Canada's Assisted Human Reproduction Act is long overdue for Parliamentary review. We argue that the current regulation of research using human reproductive materials is not proportionate, not responsive to the uncertain threats posed to human and environmental health and safety, and is not considerate of diverse values in a democratic society. We propose tailored regulatory carve-outs for in vitro research for currently prohibited activities, such as gene editing, and for the exercise of Ministerial Discretion for access by Canadians to experimental in vivo interventions that are currently prohibited, such as mitochondrial replacement therapy. Our recommendations are bounded by constitutional constraints that recognize political and practical challenges in keeping oversight of this research under Federal jurisdiction, whether conducted in academic or private sectors. The proposed nuanced regulatory scheme should be overseen by a new national Agency, modeled on a blend of the Canadian Stem Cell Oversight Committee and Assisted Human Reproduction Canada.
KW - assisted reproductive technologies
KW - Canada
KW - constitutional law
KW - criminal law
KW - germline gene editing
KW - in vitro research
KW - mitochondrial replacement therapy
KW - regulation
UR - http://www.scopus.com/inward/record.url?scp=85071048974&partnerID=8YFLogxK
U2 - 10.3389/fmed.2019.00157
DO - 10.3389/fmed.2019.00157
M3 - Article
AN - SCOPUS:85071048974
SN - 2296-858X
VL - 6
JO - Frontiers in Medicine
JF - Frontiers in Medicine
M1 - 157
ER -